Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3OC6H4OH
CAS Number:
Molecular Weight:
124.14
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
205-754-6
Beilstein/REAXYS Number:
1209898
MDL number:
Assay:
96%
Form:
liquid
Quality Level
assay
96%
form
liquid
refractive index
n20/D 1.552 (lit.)
bp
113-115 °C/5 mmHg (lit.)
density
1.131 g/mL at 25 °C (lit.)
SMILES string
COc1cccc(O)c1
InChI
1S/C7H8O2/c1-9-7-4-2-3-6(8)5-7/h2-5,8H,1H3
InChI key
ASHGTJPOSUFTGB-UHFFFAOYSA-N
Application
3-Methoxyphenol was used in synthesis of:
- C(4) symmetric calix[4]resorcinarene
- 2-nitroso-5-methoxyphenol
- 6-methoxy-2(3H)-benzoxazolone
Still not finding the right product?
Explore all of our products under 3-Methoxyphenol
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
233.6 °F - closed cup
flash_point_c
112 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Improved procedures for the preparation of 2-nitro-5-methoxyphenol and 6-methoxy-2 (3H)-benzoxazolone from 3-methoxyphenol.
Maleski RJ.
Synthetic Communications, 23(3), 343-348 (1993)
Majid Y Moridani et al.
Chemico-biological interactions, 142(3), 317-333 (2002-11-28)
A tyrosinase-directed therapeutic approach for malignant melanoma therapy uses the depigmenting phenolic agents such as 4-hydroxyanisole (4-HA) to form cytotoxic o-quinones. However, renal and hepatic toxicity was reported as side effects in a recent 4-HA clinical trial. In search of
Alejandro Cordero Vargas et al.
Organic letters, 5(20), 3717-3719 (2003-09-26)
[reaction: see text] A short synthesis of (+/-)-10-norparvulenone and (+/-)-O-methylasparvenone was developed starting from commercially available m-methoxyphenol, hinging on a xanthate-mediated addition-cyclization sequence for the construction of the alpha-tetralone subunit.

